Impact of mapped EQ-5D utilities on cost-effectiveness analysis: in the case of dialysis treatments
- PMID: 29948432
- PMCID: PMC6394787
- DOI: 10.1007/s10198-018-0987-x
Impact of mapped EQ-5D utilities on cost-effectiveness analysis: in the case of dialysis treatments
Abstract
Objectives: This study aimed to evaluate the performance of EQ-5D data mapped from SF-12 in terms of estimating cost effectiveness in cost-utility analysis (CUA). The comparability of SF-6D (derived from SF-12) was also assessed.
Methods: Incremental quality-adjusted life years (QALYs) and incremental cost-effectiveness ratios (ICERs) were calculated based on two Markov models assessing the cost effectiveness of haemodialysis (HD) and peritoneal dialysis (PD) using utility values based on EQ-5D-5L, EQ-5D using three direct-mapping algorithms and two response-mapping algorithms (mEQ-5D), and SF-6D. Bootstrap method was used to estimate the 95% confidence interval (percentile method) of incremental QALYs and ICERs with 1000 replications for the utilities.
Results: In both models, compared to the observed EQ-5D values, mEQ-5D values expressed much lower incremental QALYs (range - 14.9 to - 33.2%) and much higher ICERs (range 17.5 to 49.7%). SF-6D also estimated lower incremental QALYs (- 29.0 and - 14.9%) and higher ICERs (40.9 and 17.5%) than did the observed EQ-5D. The 95% confidence interval of incremental QALYs and ICERs confirmed the lower incremental QALYs and higher ICERs estimated using mEQ-5D and SF-6D.
Conclusion: Compared to observed EQ-5D, EQ-5D mapped from SF-12 and SF-6D would under-estimate the QALYs gained in cost-utility analysis and thus lead to higher ICERs. It would be more sensible to conduct CUA studies using directly collected EQ-5D data and to designate one single preference-based measure as reference case in a jurisdiction to achieve consistency in healthcare decision-making.
Keywords: Cost-effectiveness; Dialysis; EQ-5D; Mapping; SF-6D.
Conflict of interest statement
ND is an employee of the Office of Health Economics, a registered charity, which receives funding from a variety of sources, including the Association of the British Pharmaceutical Industry. ND and NL are members of the EuroQol Group.
Figures
Similar articles
-
Cost-Utility Analysis Using EQ-5D-5L Data: Does How the Utilities Are Derived Matter?Value Health. 2019 Jan;22(1):45-49. doi: 10.1016/j.jval.2018.05.008. Epub 2018 Jul 4. Value Health. 2019. PMID: 30661633
-
SF-6D and EQ-5D result in widely divergent incremental cost-effectiveness ratios in a clinical trial of older women: implications for health policy decisions.Osteoporos Int. 2012 Jul;23(7):1849-57. doi: 10.1007/s00198-011-1770-3. Epub 2011 Sep 10. Osteoporos Int. 2012. PMID: 21909728 Free PMC article. Clinical Trial.
-
The impact of differences in EQ-5D and SF-6D utility scores on the acceptability of cost-utility ratios: results across five trial-based cost-utility studies.Value Health. 2010 Mar-Apr;13(2):222-9. doi: 10.1111/j.1524-4733.2009.00669.x. Epub 2009 Oct 29. Value Health. 2010. PMID: 19878492
-
Which multi-attribute utility instruments are recommended for use in cost-utility analysis? A review of national health technology assessment (HTA) guidelines.Eur J Health Econ. 2020 Nov;21(8):1245-1257. doi: 10.1007/s10198-020-01195-8. Epub 2020 Jun 8. Eur J Health Econ. 2020. PMID: 32514643 Free PMC article. Review.
-
Comparison of direct and indirect methods of estimating health state utilities for resource allocation: review and empirical analysis.BMJ. 2009 Jul 22;339:b2688. doi: 10.1136/bmj.b2688. BMJ. 2009. PMID: 22128393 Free PMC article. Review.
Cited by
-
Mapping the kidney disease quality of life 36-item short form survey (KDQOL-36) to the EQ-5D-3L and the EQ-5D-5L in patients undergoing dialysis.Eur J Health Econ. 2019 Nov;20(8):1195-1206. doi: 10.1007/s10198-019-01088-5. Epub 2019 Jul 23. Eur J Health Econ. 2019. PMID: 31338698 Free PMC article.
-
An examination of machine learning to map non-preference based patient reported outcome measures to health state utility values.Health Econ. 2022 Aug;31(8):1525-1557. doi: 10.1002/hec.4503. Epub 2022 Jun 15. Health Econ. 2022. PMID: 35704682 Free PMC article.
-
Mapping Kansas City cardiomyopathy, Seattle Angina, and minnesota living with heart failure to the MacNew-7D in patients with heart disease.Qual Life Res. 2024 Aug;33(8):2151-2163. doi: 10.1007/s11136-024-03676-2. Epub 2024 Jun 5. Qual Life Res. 2024. PMID: 38839680 Free PMC article.
-
Comparing the performance of the EQ-5D-3 L and the EQ-5D-5 L in an elderly Chinese population.Health Qual Life Outcomes. 2020 Apr 9;18(1):97. doi: 10.1186/s12955-020-01324-0. Health Qual Life Outcomes. 2020. PMID: 32272976 Free PMC article.
-
Non-disease specific patient-reported outcome measures of health-related quality of life in juvenile idiopathic arthritis: a systematic review of current research and practice.Rheumatol Int. 2022 Feb;42(2):191-203. doi: 10.1007/s00296-021-05077-x. Epub 2021 Dec 31. Rheumatol Int. 2022. PMID: 34971434 Free PMC article.
References
-
- NICE: NICE Guide to the methods of technology appraisal 2013. https://www.nice.org.uk/process/pmg9/chapter/the-reference-case#measurin... (2013). Accessed 15 Aug 2017 - PubMed
-
- CADTH: Guidelines for the Economic Evaluation of Health Technologies: Canada. https://www.cadth.ca/about-cadth/how-we-do-it/methods-and-guidelines/gui... (2017). Accessed 12 Dec 2017
-
- PBS: Guidelines for preparing submissions to the Pharmaceutical Benefits Advisory Committee (Version 4.2). http://www.pbs.gov.au/info/industry/listing/procedure-guidance/4-presubm... (2017). Accessed 12 Dec 2017
-
- SMC: Guidance to manufacturers for completion of New Product Assessment Form (NPAF). https://www.scottishmedicines.org.uk/files/submissionprocess/Guidance_on... (2017). Accessed 12 Dec 2017
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases